Dragon Pharma Cagrilintide 10 mg - Amylin Research Peptide Vial

Dragon Pharma Cagrilintide 10 mg - Long-Acting Amylin Analogue

Dragon Pharma Cagrilintide 10 mg supplies the amylin analogue cagrilintide as a lyophilised 10 mg research vial. It is an investigational peptide with no approved label and no assigned ATC code, developed for metabolic research in the same clinical area as the GLP-1 peptides, but it does not act on the GLP-1 receptor. Cagrilintide for sale from a GMP manufacturer with independent testing and a Certificate of Analysis on file per batch.

• Cagrilintide 10 mg per lyophilised research vial
• Long-acting amylin receptor agonist (code GLXC-26801)
• Reference half-life 159 to 195 hours in phase 1b data
• GMP-manufactured, HPLC-verified, COA on file per batch

How Cagrilintide Works

Cagrilintide is a long-acting analogue of amylin, the satiety hormone co-secreted with insulin by pancreatic beta cells. Amylin receptors sit in the area postrema and other hindbrain regions, so the signal reaches appetite control through a different route from the incretin peptides: it slows gastric emptying, reduces meal size and lowers food intake without touching the GLP-1 receptor. That is why cagrilintide is studied both alone and next to Semaglutide, including a phase 2 arm that combined 2.4 mg cagrilintide with 2.4 mg semaglutide.

Research Amounts and Handling

No human dose is approved for this vial, so every figure is research practice. Phase 1b studied 0.16 to 4.5 mg subcutaneously once weekly, and the reference half-life of 159 to 195 hours, with a peak at 24 to 72 hours, is what supports that weekly interval; for comparison semaglutide measured 145 to 165 hours in the same study. Because accumulation matters at a week-long half-life, laboratory work models steady state rather than single doses. Reconstitute the 10 mg vial with bacteriostatic water: 2 ml gives 5 mg per ml and 1 ml gives 10 mg per ml. Store the powder at 2-8 C away from light and the solution refrigerated.

Quality & Authenticity

Every batch is produced under GMP conditions and checked by independent HPLC, with the Certificate of Analysis held for the batch. In the phase 2 data about 31.6% of participants lost at least 15% of body mass against about 4.7% on placebo, so the appetite signal is real in a research setting. Cagrilintide is not interchangeable with Tirzepatide or Retatrutide, which act on incretin receptors, and it is not an approved therapy.

For laboratory research only. Consult a healthcare professional before use.

Consult a healthcare professional before any cycle. Doses are common community protocols.